These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 19754358

  • 1. Sunitinib (SUTENT, SU11248) suppresses tumor growth and induces apoptosis in xenograft models of human hepatocellular carcinoma.
    Huynh H, Ngo VC, Choo SP, Poon D, Koong HN, Thng CH, Toh HC, Zheng L, Ong LC, Jin Y, Song IC, Chang AP, Ong HS, Chung AY, Chow PK, Soo KC.
    Curr Cancer Drug Targets; 2009 Sep; 9(6):738-47. PubMed ID: 19754358
    [Abstract] [Full Text] [Related]

  • 2. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
    Bagi CM, Gebhard DF, Andresen CJ.
    Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
    [Abstract] [Full Text] [Related]

  • 3. Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation.
    Huynh H, Choo SP, Toh HC, Tai WM, Chung AY, Chow PK, Ong R, Soo KC.
    Curr Cancer Drug Targets; 2011 Oct; 11(8):944-53. PubMed ID: 21834756
    [Abstract] [Full Text] [Related]

  • 4. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
    Castillo-Avila W, Piulats JM, Garcia Del Muro X, Vidal A, Condom E, Casanovas O, Mora J, Germà JR, Capellà G, Villanueva A, Viñals F.
    Clin Cancer Res; 2009 May 15; 15(10):3384-95. PubMed ID: 19417025
    [Abstract] [Full Text] [Related]

  • 5. Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma.
    Huynh H, Ong R, Soo KC.
    Angiogenesis; 2012 Mar 15; 15(1):59-70. PubMed ID: 22187171
    [Abstract] [Full Text] [Related]

  • 6. Effects of targeting the VEGF and PDGF pathways in diffuse orthotopic glioma models.
    Navis AC, Hamans BC, Claes A, Heerschap A, Jeuken JW, Wesseling P, Leenders WP.
    J Pathol; 2011 Apr 15; 223(5):626-34. PubMed ID: 21341272
    [Abstract] [Full Text] [Related]

  • 7. Sunitinib suppresses tumor growth and metastases in a highly metastatic mouse mammary cancer model.
    Tanaka Y, Shibata MA, Morimoto J, Otsuki Y.
    Anticancer Res; 2011 Apr 15; 31(4):1225-34. PubMed ID: 21508369
    [Abstract] [Full Text] [Related]

  • 8. Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma.
    Huynh H, Chow PK, Tai WM, Choo SP, Chung AY, Ong HS, Soo KC, Ong R, Linnartz R, Shi MM.
    J Hepatol; 2012 Mar 15; 56(3):595-601. PubMed ID: 22027573
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer.
    Awasthi N, Zhang C, Ruan W, Schwarz MA, Schwarz RE.
    PLoS One; 2012 Mar 15; 7(6):e38477. PubMed ID: 22723862
    [Abstract] [Full Text] [Related]

  • 10. Molecular targeting of VEGF/VEGFR signaling by the anti-VEGF monoclonal antibody BD0801 inhibits the growth and induces apoptosis of human hepatocellular carcinoma cells in vitro and in vivo.
    Liu L, Qin S, Zheng Y, Han L, Zhang M, Luo N, Liu Z, Gu N, Gu X, Yin X.
    Cancer Biol Ther; 2017 Mar 04; 18(3):166-176. PubMed ID: 28368741
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of eukaryotic initiation factor 4E phosphorylation by cercosporamide selectively suppresses angiogenesis, growth and survival of human hepatocellular carcinoma.
    Liu Y, Sun L, Su X, Guo S.
    Biomed Pharmacother; 2016 Dec 04; 84():237-243. PubMed ID: 27662474
    [Abstract] [Full Text] [Related]

  • 12. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
    Huang D, Ding Y, Li Y, Luo WM, Zhang ZF, Snider J, Vandenbeldt K, Qian CN, Teh BT.
    Cancer Res; 2010 Feb 01; 70(3):1053-62. PubMed ID: 20103629
    [Abstract] [Full Text] [Related]

  • 13. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma.
    Huynh H, Ngo VC, Fargnoli J, Ayers M, Soo KC, Koong HN, Thng CH, Ong HS, Chung A, Chow P, Pollock P, Byron S, Tran E.
    Clin Cancer Res; 2008 Oct 01; 14(19):6146-53. PubMed ID: 18829493
    [Abstract] [Full Text] [Related]

  • 14. Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma.
    de Boüard S, Herlin P, Christensen JG, Lemoisson E, Gauduchon P, Raymond E, Guillamo JS.
    Neuro Oncol; 2007 Oct 01; 9(4):412-23. PubMed ID: 17622648
    [Abstract] [Full Text] [Related]

  • 15. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
    Liu Y, Poon RT, Li Q, Kok TW, Lau C, Fan ST.
    Cancer Res; 2005 May 01; 65(9):3691-9. PubMed ID: 15867364
    [Abstract] [Full Text] [Related]

  • 16. Sunitinib.
    Rini BI.
    Expert Opin Pharmacother; 2007 Oct 01; 8(14):2359-69. PubMed ID: 17927489
    [Abstract] [Full Text] [Related]

  • 17. Therapeutic effects of the PKR inhibitor C16 suppressing tumor proliferation and angiogenesis in hepatocellular carcinoma in vitro and in vivo.
    Watanabe T, Ninomiya H, Saitou T, Takanezawa S, Yamamoto S, Imai Y, Yoshida O, Kawakami R, Hirooka M, Abe M, Imamura T, Hiasa Y.
    Sci Rep; 2020 Mar 20; 10(1):5133. PubMed ID: 32198380
    [Abstract] [Full Text] [Related]

  • 18. Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies.
    Zhu AX, Duda DG, Sahani DV, Jain RK.
    Cancer J; 2009 Mar 20; 15(4):263-8. PubMed ID: 19672141
    [Abstract] [Full Text] [Related]

  • 19. Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma.
    Huynh H, Chow PK, Palanisamy N, Salto-Tellez M, Goh BC, Lee CK, Somani A, Lee HS, Kalpana R, Yu K, Tan PH, Wu J, Soong R, Lee MH, Hor H, Soo KC, Toh HC, Tan P.
    J Hepatol; 2008 Jul 20; 49(1):52-60. PubMed ID: 18490075
    [Abstract] [Full Text] [Related]

  • 20. The preventative effects of sunitinib malate observed in the course from non-castration to castration LNCaP xenograft prostate tumors.
    Jing C, Ning J, Yuanjie N.
    J Cancer Res Clin Oncol; 2012 Dec 20; 138(12):2137-43. PubMed ID: 22868821
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.